Page 2 - Pharma Exports

Aurobindo Pharma's new injectable facility get 10 observations from US FDA

"The observations are procedural and will be responded to within the stipulated time," the company stated in a regulatory filing

USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

The US health regulator has pulled up Intas Pharmaceuticals for manufacturing lapses, including violation of current good manufacturing practice (CGMP) regulation, at its Ahmedabad-based plant. In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. The USFDA inspected the facility from May 1-12, 2023. "This warning letter summarises significant violations of CGMP regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," it noted. In the warning letter, the health regulator pointed out the company "failed to exercise its responsibility to ensure drug products manufactured

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Indian pharma exports to Iran have declined from $205.1 million in FY20 to $59.14 million in FY23. Iran's rupee reserves have depleted as India ceased oil imports from the country in mid-2019

Centre extends deadline for track and trace system for pharma exports

The extension applies to both Small Scale Industries (SSI) and non-SSI manufactured drugs

Pharma exports likely to touch all-time high of $27 bn in FY23 riding on EU

Better figure expected despite global headwinds; India has so far exported pharma products worth $16.57 bn during April-November this year

Indian pharma exports rise by 4.22% to $14.57 bn during April-Oct

Pharmaceutical exports from India registered a growth of 4.22 per cent to reach USD 14.57 billion during the April-October period despite a negative trend last month, according to a senior official of an export promotion body under Government of India. Udaya Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India (Pharmexcil) which is an organisation under the Ministry of Commerce, said he was hopeful of ending the current fiscal at around USD 27 billion as against USD 24.62 billion during the last financial year. "There was a dip (-0.32 per cent) in July and (-5.45 per cent) and there was 8.47 per cent positive growth in September. I am optimistic that it will be revived in the coming months and may touch USD 27 billion at the end of the fiscal," Bhaskar told PTI. During the same period last fiscal, the exports fetched USD 13.98 billion. USA, Canada and Mexico (NAFTA countries), Europe and Africa account for 67.5 per cent (nearly USD 5 billion) of the total

India's pharmaceutical exports have grown by 138% since 2013-14: Mandaviya

India's pharma exports have increased 138% in April-October 2022-23 compared to the same period of 2013-14, the health minister said

India's pharma exports touch Rs 1.8 trillion in FY22, flat over FY21

India ranks third worldwide for production in terms of volume and 14th by value, says commerce ministry.

Pharma exports touch Rs 1.83 trillion in 2021-22: Commerce ministry

The exports in 2021-22 sustained a positive growth despite the global trade disruptions and drop in demand for COVID related medicines

Indian companies stay put in Russia but pharma exports could be hit

Executives at Indian pharma companies Torrent Pharmaceuticals and Zydus Lifesciences said they saw little or no impact on sales due to the Ukraine conflict.

Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode

An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority

Sluggish exports may cap pharma YoY revenue growth in FY22, says Crisil

Revenue growth of India's pharmaceutical sector is expected to "moderate" to 9 per cent in FY22, as compared with a healthy rise of 12.5 per cent during the previous fiscal, Crisil said

India's exports rise nearly 40% in second week of August, shows data

Engineering goods witnessed the maximum increase during the week, owing to higher demand from US and Italy

Indian pharma exports grow at 18% to $24.44 billion in FY 21 from $20.58 bn

Pharma exports from India witnessed over 18 per cent growth to USD 24.44 billion during the last financial year against USD 20.58 billion in FY20

Feb exports dip 0.25% after rising three months due to uncertainties abroad

Exporters also cite container shortage; imports continue to rise due to revival in domestic economy and high commodity prices

Pharmaceutical exports jumped 12.43% during April-December 2021

The exports grew to $17.57 billion, Parliament was informed on Friday

Exports rise 5.4% in January; trade deficit narrows to $14.75 billion

Rise in both exports and imports signals recovery is strengthening: Experts

Both exports and imports record growth in December; first time since Feb

Trade deficit at 25-month high as imports surge 8% after continuous declines; Data shows industrial activity picking up in December

Pharma exports likely to get a boost on coronavirus vaccine shots

However, he said that many countries, especially the European Union, are likely to step up production and increase their portfolios in an attempt to reduce import reliability.

Exim Bank pegs exports to grow around 8% in Dec after two months of decline

For Q3 as a whole, it sees outbound shipment declining by 1.77%